ClinicalTrials.gg
CompletedNCT00530816Updated May 2, 2017Results posted

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

A Phase 2 interventional study of carfilzomib in Multiple Myeloma, sponsored by Amgen. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
19th of 113
164 · median 54
Started
2007
with 2 others
Phase 2
50 of 113
6 open now
Registered
3rd of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 19th largest by enrollment, is one of 3 that started in 2007, is one of 50 in phase 2, and was the 3rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.

Read the detailed description

Two groups of patients with multiple myeloma were initially studied: bortezomib-naïve and bortezomib-treated. Following Amendment 2, only bortezomib-naïve patients were enrolled. Study results were reported in 2 parts, depending on whether a patient received prior bortezomib.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Disease Related

  • Multiple myeloma
  • Subjects must have , defined as one or more of the following:

    • Serum M-protein ≥ 1 g/dL
    • Urine M-protein ≥ 200 mg/24 hours
  • Subjects must have been responsive (i.e., achieve a minimal response [MR] or better) to standard, therapy
  • or progressive disease after at least one, but no more than three, prior therapeutic treatments or regimens for multiple myeloma. Refractory disease is defined as ≤ 25% response or progression during therapy or within 60 days after completion of therapy. Induction therapy and stem cell transplant will be considered as one regimen

Demographic

  • Males and females ≥18 years of age
  • of more than three months
  • (ECOG) Performance Status of 0-2

Laboratory

  • Adequate hepatic function, with \< 2.0 times the , and (AST) and alanine aminotransferase (ALT) of \< 3.0 times the upper limit of normal
  • Uric acid, if elevated, must be corrected to within laboratory normal range prior to dosing
  • Total white blood cell (WBC) count ≥ 2,000/mm³, > 1,000/mm³, ≥ 8.0 g/dL, and count > 50,000/mm³
  • Subjects should be platelet transfusion independent
  • Screening absolute neutrophil count (ANC) should be independent of granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) support for ≥ 1 week and of pegylated G-CSF for ≥ 2 weeks
  • Subjects may receive red blood cell (RBC) transfusion or receive supportive care such as erythropoietin and darbepoetin in accordance with institutional guidelines
  • Calculated or measured of ≥ 30 mL/minute, calculated using the formula of Cockcroft and Gault [(140 - Age) X Mass (kg) / (72 X Creatinine mg/dL)]. Multiply result by 0.85 if female.
  • Serum creatinine ≤ 2 mg/dL

Ethical / Other

  • Written in accordance with federal, local, and institutional guidelines
  • Female subjects of must have a negative serum pregnancy test within seven days of the first dose and agree to use dual methods of during and for 3 months following last dose of drug. Post menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from a pregnancy test. Male subjects must use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with a female of child-bearing potential.
  • Subjects must be able to receive outpatient treatment and laboratory monitoring at the institute that administers agent.

Exclusion criteria

Exclusion Criteria:

Disease Related

  • Multiple Myeloma Immunoglobulin M (IgM)
  • Subjects previously treated with any proteasome inhibitor (for Part 2 Proteasome Inhibitor - Naïve only, criteria added at Amendment 2)
  • Subjects must not be primary to standard therapy
  • Subjects with non-secretory multiple myeloma, defined as \< 1 g/dL M-protein in serum, \< 200 mg/24 hour M-protein in urine
  • Subjects with disease measurable only by serum free light chain (SFLC) analysis
  • therapy (prednisone >10 mg/day orally or equivalent) within the last three weeks
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Plasma cell leukemia
  • Chemotherapy with approved or investigative anticancer therapeutics, including steroid therapy, within the three weeks prior to first dose
  • Radiation therapy or immunotherapy in the previous four weeks; localized radiation therapy within 1 week prior to first dose
  • Participation in an therapeutic study within three weeks or within five drug half-lives (t1/2) prior to first dose, whichever time is greater
  • Prior treatment with carfilzomib

Concurrent Conditions

  • Major surgery within three weeks before Day 1
  • Congestive heart failure ( class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction in the previous six months
  • Acute active infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first dose
  • Known or suspected human immunodeficiency () infection or subjects who are HIV seropositive
  • Active hepatitis A, B, or C infection
  • Non-hematologic within the past three years except a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, or c) prostate cancer \< Gleason Grade 6 with stable prostate-specific antigen (PSA)
  • Subjects with treatment related myelodysplastic syndrome
  • Significant neuropathy (Grade 3, 4 or Grade 2 with pain) at the time of study initiation
  • Subjects with known to receiving allopurinol
  • Subjects in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g., due to pre-existing pulmonary, cardiac, or renal impairment
  • Subjects with known or suspected amyloidosis Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
  • Any medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give

Ethical / Other

  • Female subjects who are pregnant or lactating
  • Serious psychiatric or medical conditions that could interfere with treatment
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Carfilzomib

    Participants received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles. Starting with Amendment 3, if all doses in Cycle 1 were well-tolerated the dose was escalated to 27 mg/m² IV for subsequent cycles.

    Drug: carfilzomib

Interventions

  • Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.

    Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection

06

What researchers measure

Primary outcomes

  1. Best Overall Response Rate (ORR) in the Response Evaluable Subset Population

    ORR is defined as the percentage of patients who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) determined by Independent Review Committee (IRC). Responses were assessed according to International Uniform Response Criteria for Multiple Myeloma, documented by 2 consecutive assessments made at any time before the start of new therapy. sCR: CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. CR: absence of M-protein in serum and urine by immunofixation, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow. VGPR: serum and urine M-proteins detectable by immunofixation but not by electrophoresis or a ≥ 90% reduction in serum M-protein with urine M-protein level \< 100 mg/24 hours. PR: ≥ 50% reduction of serum M-protein and in urine of ≥ 90% or to \< 200 mg per 24 hours.

    Time frame: Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.

Secondary outcomes

  1. Best Overall Response Rate (ORR) in the Response Evaluable Population

    ORR is defined as the percentage of patients who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) determined by Independent Review Committee (IRC). Responses were assessed according to International Uniform Response Criteria for Multiple Myeloma, documented by 2 consecutive assessments made at any time before the start of new therapy. sCR: CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. CR: absence of M-protein in serum and urine by immunofixation, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow. VGPR: serum and urine M-proteins detectable by immunofixation but not by electrophoresis or a ≥ 90% reduction in serum M-protein with urine M-protein level \< 100 mg/24 hours. PR: ≥ 50% reduction of serum M-protein and in urine of ≥ 90% or to \< 200 mg per 24 hours.

    Time frame: Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, End of Study, 30 days after last dose; median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.

  2. Clinical Benefit Rate (CBR)

    Clinical Benefit Rate is defined as the percentage of participants with a best overall response of minimal response (MR) or better, i.e., a best overall response of sCR, CR, VGPR, PR, or MR. MR was defined as outlined by European Group for Blood and Marrow Transplantation (EBMT) criteria, defined as reduction of M-protein in serum of 25% to 49% and in urine of 50% to 89%, maintained for 6 weeks.

    Time frame: Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.

  3. Duration of Response (DOR)

    DOR is defined as the time from first evidence of PR or better to disease progression assessed by the IRC or death due to any cause. Patients lost to follow-up prior to disease progression or who were alive without disease progression before the analysis cutoff date were censored at the last disease assessment. Progressive disease was defined as any of the following: * An increase of M-protein in serum (absolute increase ≥ 0.5 g/dL) or urine (absolute increase ≥ 200 mg/24 hours) of \> 25% from the nadir (if not zero). * Percentage of plasma cells in bone marrow ≥ 10%. * New or increased size of bone lesions or new plasmacytomas. * Patients without measurable serum and urine M-protein: 25% increase from nadir in the difference between involved and uninvolved FLC levels and absolute increase \>10 mg/dL. * Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL) attributed solely to the proliferative disorder. Median DOR was estimated using Kaplan-Meier methods.

    Time frame: Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2.

  4. Time to Progression (TTP)

    Time to Progression is defined as the time from the start of treatment to IRC-determined disease progression. Patients who were lost to follow-up prior to documentation of disease progression, or who died before documentation of disease progression or who were alive and did not have documentation of disease progression before the data analysis cut-off date were censored at the last disease assessment. Median TTP was estimated using the Kaplan-Meier method.

    Time frame: Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2. Median follow-up time was 13.4 months for Part 1 and 11.5 months in Part 2.

  5. Progression-free Survival (PFS)

    Progression-free Survival (PFS) is defined as the time from start of treatment to IRC determined disease progression or death due to any cause. Patients who were lost to follow-up prior to documentation of disease progression and patients who were alive without disease progression before a data analysis cut-off date were censored at the last disease assessment. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2. Median follow-up time was 13.4 months for Part 1 and 11.5 months in Part 2.

  6. Overall Survival (OS)

    Overall Survival is defined as the time from the start of study treatment to date of death due to any cause. Patients who were alive or lost to follow-up as of the data analysis cut-off date for the final OS analysis were censored at the date the patient was last known to be alive. Median OS was estimated using the Kaplan-Meier method.

    Time frame: Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 19 November 2012 for Part 1 and 07 January 2013 for Part 2. Median follow-up time was 19.1 months for Part 1 and 35.9 months in Part 2.

07

Results

Posted Dec 3, 2015

Participant flow

This study enrolled patients with multiple myeloma (MM) who had relapsed or refractory disease after at least 1 but no more than 3 prior therapeutic treatments or regimens. The first patient enrolled on 24 September 2007; the last patient was enrolled and received carfilzomib on 28 May 2009.

Participant flow — Overall Study
MilestonePart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
Started355970
Completed91729
Not completed264241
Withdrew: Progressive disease162424
Withdrew: Adverse event6137
Withdrew: Other334
Withdrew: Withdrawal by subject126

Outcome measures

PrimaryBest Overall Response Rate (ORR) in the Response Evaluable Subset Population

ORR is defined as the percentage of patients who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) determined by Independent Review Committee (IRC). Responses were assessed according to International Uniform Response Criteria for Multiple Myeloma, documented by 2 consecutive assessments made at any time before the start of new therapy. sCR: CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. CR: absence of M-protein in serum and urine by immunofixation, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow. VGPR: serum and urine M-proteins detectable by immunofixation but not by electrophoresis or a ≥ 90% reduction in serum M-protein with urine M-protein level \< 100 mg/24 hours. PR: ≥ 50% reduction of serum M-protein and in urine of ≥ 90% or to \< 200 mg per 24 hours.

Time frame:
Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.
Reported as:
Number · percentage of participants
Best Overall Response Rate (ORR) in the Response Evaluable Subset Population
percentage of participantsPart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
Best Overall Response Rate (ORR) in the Response Evaluable Subset Population16.1 (5.45 to 33.73)39.6 (26.5 to 54.0)53.0 (40.3 to 65.4)
SecondaryBest Overall Response Rate (ORR) in the Response Evaluable Population

ORR is defined as the percentage of patients who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) determined by Independent Review Committee (IRC). Responses were assessed according to International Uniform Response Criteria for Multiple Myeloma, documented by 2 consecutive assessments made at any time before the start of new therapy. sCR: CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. CR: absence of M-protein in serum and urine by immunofixation, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow. VGPR: serum and urine M-proteins detectable by immunofixation but not by electrophoresis or a ≥ 90% reduction in serum M-protein with urine M-protein level \< 100 mg/24 hours. PR: ≥ 50% reduction of serum M-protein and in urine of ≥ 90% or to \< 200 mg per 24 hours.

Time frame:
Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, End of Study, 30 days after last dose; median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.
Reported as:
Number · percentage of participants
Best Overall Response Rate (ORR) in the Response Evaluable Population
percentage of participantsPart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
Best Overall Response Rate (ORR) in the Response Evaluable Population17.1 (6.56 to 33.65)42.4 (29.6 to 55.9)52.2 (39.7 to 64.6)
SecondaryClinical Benefit Rate (CBR)

Clinical Benefit Rate is defined as the percentage of participants with a best overall response of minimal response (MR) or better, i.e., a best overall response of sCR, CR, VGPR, PR, or MR. MR was defined as outlined by European Group for Blood and Marrow Transplantation (EBMT) criteria, defined as reduction of M-protein in serum of 25% to 49% and in urine of 50% to 89%, maintained for 6 weeks.

Time frame:
Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.
Reported as:
Median · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsPart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
Clinical Benefit Rate (CBR)31.4 (16.85 to 49.29)59.3 (45.7 to 71.9)64.2 (51.5 to 75.5)
SecondaryDuration of Response (DOR)

DOR is defined as the time from first evidence of PR or better to disease progression assessed by the IRC or death due to any cause. Patients lost to follow-up prior to disease progression or who were alive without disease progression before the analysis cutoff date were censored at the last disease assessment. Progressive disease was defined as any of the following: * An increase of M-protein in serum (absolute increase ≥ 0.5 g/dL) or urine (absolute increase ≥ 200 mg/24 hours) of \> 25% from the nadir (if not zero). * Percentage of plasma cells in bone marrow ≥ 10%. * New or increased size of bone lesions or new plasmacytomas. * Patients without measurable serum and urine M-protein: 25% increase from nadir in the difference between involved and uninvolved FLC levels and absolute increase \>10 mg/dL. * Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL) attributed solely to the proliferative disorder. Median DOR was estimated using Kaplan-Meier methods.

Time frame:
Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2.
Reported as:
Median · months
Duration of Response (DOR)
monthsPart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
Duration of Response (DOR)NA (10.6 to NA)13.1 (7.2 to NA)NA (NA to NA)
SecondaryTime to Progression (TTP)

Time to Progression is defined as the time from the start of treatment to IRC-determined disease progression. Patients who were lost to follow-up prior to documentation of disease progression, or who died before documentation of disease progression or who were alive and did not have documentation of disease progression before the data analysis cut-off date were censored at the last disease assessment. Median TTP was estimated using the Kaplan-Meier method.

Time frame:
Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2. Median follow-up time was 13.4 months for Part 1 and 11.5 months in Part 2.
Reported as:
Median · months
Time to Progression (TTP)
monthsPart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
Time to Progression (TTP)4.6 (1.9 to 11.1)8.3 (6.0 to 12.3)NA (11.3 to NA)
SecondaryProgression-free Survival (PFS)

Progression-free Survival (PFS) is defined as the time from start of treatment to IRC determined disease progression or death due to any cause. Patients who were lost to follow-up prior to documentation of disease progression and patients who were alive without disease progression before a data analysis cut-off date were censored at the last disease assessment. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2. Median follow-up time was 13.4 months for Part 1 and 11.5 months in Part 2.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
Progression-free Survival (PFS)4.6 (2.1 to 11.1)8.2 (6.0 to 12.3)NA (11.3 to NA)
SecondaryOverall Survival (OS)

Overall Survival is defined as the time from the start of study treatment to date of death due to any cause. Patients who were alive or lost to follow-up as of the data analysis cut-off date for the final OS analysis were censored at the date the patient was last known to be alive. Median OS was estimated using the Kaplan-Meier method.

Time frame:
Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 19 November 2012 for Part 1 and 07 January 2013 for Part 2. Median follow-up time was 19.1 months for Part 1 and 35.9 months in Part 2.
Reported as:
Median · months
Overall Survival (OS)
monthsPart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
Overall Survival (OS)45.6 (28.4 to NA)NA (33.4 to NA)37.3 (27.1 to NA)

Adverse events

Collected over From the first dose of study medication until 30 days after the last dose or initiation of new, non-protocol therapy for MM, whichever was first; median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Carfilzomib 20 mg/m²—12/35 (34.3%)35/35 (100%)
Part 2: Carfilzomib 20 mg/m²—18/59 (30.5%)59/59 (100%)
Part 2: Carfilzomib 20/27 mg/m²—27/70 (38.6%)70/70 (100%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventPart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
PneumoniaInfections and infestations3/356/596/70
PyrexiaGeneral disorders2/351/593/70
HypercalcaemiaMetabolism and nutrition disorders2/350/590/70
Renal failure acuteRenal and urinary disorders1/352/593/70
Cardiac failure congestiveCardiac disorders1/352/592/70
Tumour lysis syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/352/590/70
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/352/591/70
AnaemiaBlood and lymphatic system disorders0/350/592/70
NeutropeniaBlood and lymphatic system disorders0/350/592/70
ThrombocytopeniaBlood and lymphatic system disorders1/350/590/70
Most frequent other events
Showing 10 of 142
Most frequent other events
EventPart 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²
FatigueGeneral disorders22/3542/5938/70
NauseaGastrointestinal disorders21/3532/5931/70
DyspnoeaRespiratory, thoracic and mediastinal disorders13/3529/5919/70
AnaemiaBlood and lymphatic system disorders12/3527/5925/70
VomitingGastrointestinal disorders15/3514/5914/70
CoughRespiratory, thoracic and mediastinal disorders8/3523/5921/70
DiarrhoeaGastrointestinal disorders13/3521/5918/70
PyrexiaGeneral disorders8/3521/5922/70
Blood creatinine increasedInvestigations12/3514/5910/70
LymphopeniaBlood and lymphatic system disorders6/3520/5913/70

Baseline characteristics

Safety Population: All patients enrolled on study and who received at least 1 dose of carfilzomib.

Age, Categorical
Age, Categorical(Participants)Part 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²Total
<=18 years0000
Between 18 and 65 years21293181
>=65 years14303983
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²Total
Female17272670
Male18324494
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Part 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²Total
0 (Fully Active)15292367
1 (Restrictive but ambulatory)18274287
2 (Ambulatory but unable to work)1359
Missing1001
Measurable Disease Category
Measurable Disease Category(participants)Part 1: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20 mg/m²Part 2: Carfilzomib 20/27 mg/m²Total
SPEP and UPEP361120
SPEP223947108
UPEP661022
SFLC Only46111
IgA, by Immunoglobulin Assay Only0202
Missing0011
08

Study locations

30 sites
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • Therapeutic Research Institute of Orange County
    Laguna Hills, California 92653, United States
  • Rocky Mountain Blood and Marrow Transplant Program
    Denver, Colorado 80218, United States
  • Oncology & Hematology Assoc. of W. Broward
    Tamarac, Florida 33321, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Emory University Winship Cancer Institute
    Atlanta, Georgia 404-778-5747, United States
  • Northwestern University
    Chicago, Illinois 60605, United States
  • Orchard Research
    Skokie, Illinois 60076, United States
  • University of Kentucky College of Medicine
    Lexington, Kentucky 40536-0093, United States
  • Montgomery Cancer Center
    Mount Sterling, Kentucky 40353, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109-0936, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39401, United States
  • Jackson Oncology Associates
    Jackson, Mississippi 39202, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • St. Vincent's Comprehensive Cancer Center
    New York, New York 10011, United States
  • Summa Health System
    Akron, Ohio 44304, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Dayton Clinical Oncology Program
    Dayton, Ohio 45429, United States
  • Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042, United States
  • Harrington Cancer Center
    Amarillo, Texas 79106, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Calgary
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • University of Toronto Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Royal Victoria Hospital
    Montreal, Quebec H3A 1A1, Canada
09

References and documents

Publications

  • Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3. PubMed 22555973 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Jan 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2007
First posted
Sep 18, 2007
Start
Sep 2007
Primary completionActual
Jan 2013
CompletionActual
Jul 2013
Results first posted
Dec 3, 2015
Last update
May 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00530816
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 18, 2007
Start date
Sep 2007
Primary completion
Jan 2013
Completion
Jul 2013
Results posted
Dec 3, 2015
Last update
May 2, 2017

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion